score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.3716	218.0	1.6e-05	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0	6.0	0.0	0.1468	BRAF p.V600E (Missense)	1.0	MEL-IPI_Pat39	MEL-IPI_Pat39-Tumor-SM-4DK1Z	MEL-IPI_Pat39-Normal-SM-4NFV6
Investigate Actionability	Guideline			Rearrangement	COL1A1	Fusion	COL1A1--RN7SKP71			0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Imatinib has shown clinical activity against localized and metastatic DFSP tumors containing t(17;22)(q22;q13).	National Comprehensive Cancer Network. Dermatofibrosarcoma NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf													0				COL1A1--RN7SKP71 Fusion	0.0	MEL-IPI_Pat39		
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273C	0.48	25.0	8e-06	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0.0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	7.0	0.0	0.4633	TP53 p.R273C (Missense)		MEL-IPI_Pat39	MEL-IPI_Pat39-Tumor-SM-4DK1Z	MEL-IPI_Pat39-Normal-SM-4NFV6
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Frameshift	p.K795fs	0.5172	29.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405						0	0.0	0.0	0.0	BCR p.K795fs (Frameshift)		MEL-IPI_Pat39	MEL-IPI_Pat39-Tumor-SM-4DK1Z	MEL-IPI_Pat39-Normal-SM-4NFV6
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Frameshift	p.K795fs	0.4412	34.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405						0	0.0	0.0	0.0	BCR p.K795fs (Frameshift)		MEL-IPI_Pat39	MEL-IPI_Pat39-Tumor-SM-4DK1Z	MEL-IPI_Pat39-Normal-SM-4NFV6
Biologically Relevant				Rearrangement	JAK3	Fusion	JAK3--URB1			0.0	0.0																					0				JAK3--URB1 Fusion		MEL-IPI_Pat39		
Biologically Relevant				Rearrangement	CTNNB1	Fusion	CTNNB1--MALAT1			0.0	0.0																					0				CTNNB1--MALAT1 Fusion		MEL-IPI_Pat39		
Biologically Relevant				Copy Number	ALK	Amplification				0.0	0.0																					0				ALK Amplification		MEL-IPI_Pat39	MEL-IPI_Pat39-Tumor-SM-4DK1Z	
Biologically Relevant				Copy Number	JAK2	Deletion				0.0	0.0																					0				JAK2 Deletion		MEL-IPI_Pat39	MEL-IPI_Pat39-Tumor-SM-4DK1Z	
Biologically Relevant				Copy Number	PDGFRB	Deletion				0.0	0.0																					0				PDGFRB Deletion		MEL-IPI_Pat39	MEL-IPI_Pat39-Tumor-SM-4DK1Z	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)		MEL-IPI_Pat39		
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.654																									0				COSMIC Signature (version 2) 1 (65%)		MEL-IPI_Pat39		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.289																									0				COSMIC Signature (version 2) 7 (29%)		MEL-IPI_Pat39		
